{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:05:50Z","timestamp":1788897950407,"version":"build-2803163510"},"reference-count":69,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,8,23]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Neutrophilic airway inflammation is associated with disease severity and exacerbation frequency in bronchiectasis. Neutrophil protease inhibition significantly reduced exacerbation rates in phase II and III trials in bronchiectasis, highlighting this disease feature as an important therapeutic target. Additional neutrophil targeting therapeutics are needed to reduce the burden of the disease. Herein, we describe the protocol for the AIR-NET trial, the first randomised, open-label, multifactorial, multicentre, adaptive platform trial for people with bronchiectasis, run\n                      <jats:italic>via<\/jats:italic>\n                      the EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) network, to investigate the safety and efficacy of several repurposed anti-inflammatory treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Participants with bronchiectasis confirmed by computed tomography, daily sputum production and evidence of active airway neutrophilic inflammation (based on a positive lateral flow test for neutrophil elastase (NE) activity), across 10 sites in the UK, will be randomised to one of several repurposed drugs with published evidence of effects on neutrophilic inflammation and acceptable safety profile (oral dose: disulfiram 400\u2005mg once daily; dipyridamole 200\u2005mg twice daily; doxycycline 100\u2005mg once daily; n=42 per arm) or usual care, according to arm-specific eligibility criteria, and treated for 28 days. New arms will be added to the trial through an adaptive design. The primary end-point is change from baseline in sputum NE activity (a validated biomarker and surrogate of exacerbation risk) at day 28. Key secondary end-points include time-to-first exacerbation, quality of life questionnaires, neutrophil function and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>AIR-NET will establish a multi-centre network with integrated clinical and translational capabilities for the investigation of therapies in bronchiectasis aiming to identify key anti-inflammatory mechanisms and effective re-purposed treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00719-2025","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:50:20Z","timestamp":1760629820000},"page":"00719-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network"],"prefix":"10.1183","volume":"12","author":[{"given":"Merete B.","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1692-8204","authenticated-orcid":false,"given":"Jaa Ming","family":"New","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4829-7440","authenticated-orcid":false,"given":"Jamie","family":"Stobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Band","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McLaren-Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Eke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran","family":"Singanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-520X","authenticated-orcid":false,"given":"Anand","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Loebinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-7607","authenticated-orcid":false,"given":"Sanjay H","family":"Chotirmall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0344","authenticated-orcid":false,"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2026050510152474000_12.2.00719-2025.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01033-2015"},{"key":"2026050510152474000_12.2.00719-2025.2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0091-2024"},{"key":"2026050510152474000_12.2.00719-2025.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC"},{"key":"2026050510152474000_12.2.00719-2025.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7"},{"key":"2026050510152474000_12.2.00719-2025.5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1517\/14656566.2015.1019863","article-title":"Challenges in the development of new therapies for bronchiectasis","volume":"16","author":"Chalmers","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2026050510152474000_12.2.00719-2025.6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis","volume":"166","author":"Cordeiro","year":"2024","journal-title":"Chest"},{"key":"2026050510152474000_12.2.00719-2025.7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S2213-2600(20)30504-X","article-title":"Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study","volume":"9","author":"Keir","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026050510152474000_12.2.00719-2025.8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","article-title":"Rethinking bronchiectasis as an inflammatory disease","volume":"12","author":"Long","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026050510152474000_12.2.00719-2025.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC"},{"key":"2026050510152474000_12.2.00719-2025.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.022"},{"key":"2026050510152474000_12.2.00719-2025.11","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1038\/s41467-024-50197-0","article-title":"Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations","volume":"15","author":"Katsoulis","year":"2024","journal-title":"Nat Commun"},{"key":"2026050510152474000_12.2.00719-2025.12","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.0c08130"},{"key":"2026050510152474000_12.2.00719-2025.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713"},{"key":"2026050510152474000_12.2.00719-2025.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01551-2024"},{"key":"2026050510152474000_12.2.00719-2025.15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S2213-2600(25)00019-0","article-title":"Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Zhong","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026050510152474000_12.2.00719-2025.16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050510152474000_12.2.00719-2025.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2021.11.003"},{"key":"2026050510152474000_12.2.00719-2025.18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2213-2600(23)00052-8","article-title":"Platform trials: the future of medical research?","volume":"11","author":"Burki","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026050510152474000_12.2.00719-2025.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.136"},{"key":"2026050510152474000_12.2.00719-2025.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.149"},{"key":"2026050510152474000_12.2.00719-2025.21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01147-w"},{"key":"2026050510152474000_12.2.00719-2025.22","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood.2021011525","article-title":"Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation","volume":"138","author":"Silva","year":"2021","journal-title":"Blood"},{"key":"2026050510152474000_12.2.00719-2025.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04062-5"},{"key":"2026050510152474000_12.2.00719-2025.24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aar6689"},{"key":"2026050510152474000_12.2.00719-2025.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0669-6"},{"key":"2026050510152474000_12.2.00719-2025.26","doi-asserted-by":"crossref","first-page":"e12045","DOI":"10.1002\/clt2.12045","article-title":"Topical inflammasome inhibition with disulfiram prevents irritant contact dermatitis","volume":"11","author":"Bonnekoh","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"2026050510152474000_12.2.00719-2025.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114609"},{"key":"2026050510152474000_12.2.00719-2025.28","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01966-2023"},{"key":"2026050510152474000_12.2.00719-2025.29","doi-asserted-by":"crossref","first-page":"e157342","DOI":"10.1172\/jci.insight.157342","article-title":"Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection","volume":"7","author":"Adrover","year":"2022","journal-title":"JCI Insight"},{"key":"2026050510152474000_12.2.00719-2025.30","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1021\/acsmedchemlett.3c00450","article-title":"The promiscuity of disulfiram in medicinal research","volume":"14","author":"Cvek","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"2026050510152474000_12.2.00719-2025.31","first-page":"136","article-title":"Multiple effects of dipyridamole on neutrophils and mononuclear leukocytes: adenosine-dependent and adenosine-independent mechanisms","volume":"118","author":"Colli","year":"1991","journal-title":"J Lab Clin Med"},{"key":"2026050510152474000_12.2.00719-2025.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09801-x"},{"key":"2026050510152474000_12.2.00719-2025.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(99)00173-3"},{"key":"2026050510152474000_12.2.00719-2025.34","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.089987"},{"key":"2026050510152474000_12.2.00719-2025.35","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000154607.90506.45"},{"key":"2026050510152474000_12.2.00719-2025.36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000319072","article-title":"Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells","volume":"30","author":"Guo","year":"2010","journal-title":"Cerebrovasc Dis"},{"key":"2026050510152474000_12.2.00719-2025.37","doi-asserted-by":"crossref","first-page":"636678","DOI":"10.3389\/fmolb.2021.636678","article-title":"Enhancing extracellular adenosine levels restores barrier function in acute lung injury through expression of focal adhesion proteins","volume":"8","author":"Wang","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026050510152474000_12.2.00719-2025.38","doi-asserted-by":"publisher","DOI":"10.1186\/cc10576"},{"key":"2026050510152474000_12.2.00719-2025.39","unstructured":"Electronic Medicines Compendium . Dipyridamole 200 mg prolonged release capsules, hard. Date last updated: 9 December 2022. Date last accessed: 28 July 2025. www.medicines.org.uk\/emc\/product\/14382\/smpc#gref"},{"key":"2026050510152474000_12.2.00719-2025.40","doi-asserted-by":"publisher","DOI":"10.1177\/08959374980120010501"},{"key":"2026050510152474000_12.2.00719-2025.41","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00048.2021"},{"key":"2026050510152474000_12.2.00719-2025.42","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201411-513OC"},{"key":"2026050510152474000_12.2.00719-2025.43","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00212114"},{"key":"2026050510152474000_12.2.00719-2025.44","doi-asserted-by":"crossref","first-page":"101831","DOI":"10.1016\/j.pupt.2019.101831","article-title":"Effect of doxycyline in chronic obstructive pulmonary disease \u2013 an exploratory study","volume":"58","author":"Singh","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2026050510152474000_12.2.00719-2025.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.03.008"},{"key":"2026050510152474000_12.2.00719-2025.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3630-3633.2003"},{"key":"2026050510152474000_12.2.00719-2025.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2011.08.039"},{"key":"2026050510152474000_12.2.00719-2025.48","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s12640-015-9592-2","article-title":"Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-\u03baB signaling pathways","volume":"29","author":"Santa-Cec\u00edlia","year":"2016","journal-title":"Neurotox Res"},{"key":"2026050510152474000_12.2.00719-2025.49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3389\/fimmu.2017.00857","article-title":"Doxycycline attenuates Leptospira-induced IL-1\u03b2 by suppressing NLRP3 inflammasome priming","volume":"8","author":"Zhang","year":"2017","journal-title":"Front Immunol"},{"key":"2026050510152474000_12.2.00719-2025.50","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12488"},{"key":"2026050510152474000_12.2.00719-2025.51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-9255-9-31","article-title":"Doxycycline impairs neutrophil migration to the airspaces of the lung in mice exposed to intratracheal lipopolysaccharide","volume":"9","author":"Moon","year":"2012","journal-title":"J Inflamm"},{"key":"2026050510152474000_12.2.00719-2025.52","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212463"},{"key":"2026050510152474000_12.2.00719-2025.53","first-page":"42","article-title":"High performance liquid chromatographic method for determination of doxycycline in human plasma and its application in pharmacokinetic studies","volume":"13","author":"Alsarra","year":"2005","journal-title":"Saudi Pharm J"},{"key":"2026050510152474000_12.2.00719-2025.54","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-008-6150-7"},{"key":"2026050510152474000_12.2.00719-2025.55","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/antibiotics12071152","article-title":"Oral tetracycline-class drugs in dermatology: impact of food intake on absorption and efficacy","volume":"12","author":"Tao","year":"2023","journal-title":"Antibiotics"},{"key":"2026050510152474000_12.2.00719-2025.56","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2026050510152474000_12.2.00719-2025.57","unstructured":"Cohen J . Statistical Power Analysis for the Behavioral Sciences. 2nd Edn. Abingdon, Routledge, 1988."},{"key":"2026050510152474000_12.2.00719-2025.58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026050510152474000_12.2.00719-2025.59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1740774520904346","article-title":"Adding new experimental arms to randomised clinical trials: Impact on error rates","volume":"17","author":"Choodari-Oskooei","year":"2020","journal-title":"Clin Trials"},{"key":"2026050510152474000_12.2.00719-2025.60","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1891"},{"key":"2026050510152474000_12.2.00719-2025.61","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03156-2020"},{"key":"2026050510152474000_12.2.00719-2025.62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12931-019-1272-y","article-title":"Development and initial validation of the Bronchiectasis Exacerbation and Symptom Tool (BEST)","volume":"21","author":"Artaraz","year":"2020","journal-title":"Respir Res"},{"key":"2026050510152474000_12.2.00719-2025.63","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1053"},{"key":"2026050510152474000_12.2.00719-2025.64","doi-asserted-by":"crossref","unstructured":"New BJM , Chalmers JD , Stobo J . COVID-19 platform trials: insight and lessons in clinical trial design. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024; pp. 278\u2013294. doi:10.1183\/2312508X.10021223","DOI":"10.1183\/2312508X.10021223"},{"key":"2026050510152474000_12.2.00719-2025.65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s13063-020-04584-9","article-title":"ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial","volume":"21","author":"Wilkinson","year":"2020","journal-title":"Trials"},{"key":"2026050510152474000_12.2.00719-2025.66","doi-asserted-by":"crossref","first-page":"107292","DOI":"10.1016\/j.cct.2023.107292","article-title":"Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: successes, learnings, and recommendations for future pandemics","volume":"132","author":"Buenconsejo","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2026050510152474000_12.2.00719-2025.67","doi-asserted-by":"crossref","first-page":"e243109","DOI":"10.1001\/jamanetworkopen.2024.3109","article-title":"Characteristics, progression, and output of randomized platform trials: a systematic review","volume":"7","author":"Griessbach","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026050510152474000_12.2.00719-2025.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0034-3"},{"key":"2026050510152474000_12.2.00719-2025.69","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00315-7"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00719-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:15:57Z","timestamp":1778001357000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00719-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":69,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1183\/23120541.00719-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00719-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}